One year in review 2022: systemic lupus erythematosus

Zucchi, D.; Elefante, E.; Schiliro, D.; Signorini, V.; Trentin, F.; Bortoluzzi, A.; Tani, C.

Zucchi, D.; Elefante, E.; Schiliro, D.; Signorini, V.; Trentin, F.; Bortoluzzi, A.; Tani, C..

Clinical and Experimental Rheumatology ; 40(1):4-14, 2022.

Article in English | EMBASE | ID: covidwho-2157240

ABSTRACT

ABSTRACT

Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE about pathogenetic pathways, biomarkers, and data on clinical manifestations are progressively emerging, and new drugs and new therapeutic strategies have been proposed to improve the control of disease activity. Thus, this review is aimed to summarise the most relevant data about SLE emerged during 2021, following the previous annual review of this series. © Copyright Clinical and Experimental Rheumatology 2022.

Keywords

clinical effectiveness; clinical feature; comorbidity; coronavirus disease 2019; drug efficacy; human; molecular pathology; nonhuman; patient-reported outcome; quality of life; review; systemic lupus erythematosus/dt [Drug Therapy]; systemic

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: Clinical and Experimental Rheumatology Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: Clinical and Experimental Rheumatology Year: 2022 Document Type: Article